查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813275

心臟病诊断市场预测（至 2032 年）：按产品、测试类型、生物标记、影像方式、诊断方法、年龄层、应用、最终用户和地区进行的全球分析

Heart Attack Diagnostics Market Forecasts to 2032 - Global Analysis By Product (Instruments, Consumables, Software, Services), Test Type, Biomarker, Imaging Modality, Diagnosis Method, Age Group, Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球心臟病诊断市场预计在 2025 年达到 125 亿美元，到 2032 年将达到 218 亿美元，预测期内的复合年增长率为 8.2%。

心臟病发作诊断是指用于检测和确认心肌梗塞（心肌梗塞是由心臟血流受限引起的）的医疗程序、检查和设备。这些诊断包括心臟生物标记血液检测、心电图 (ECG)、影像学检查和压力测试。它们有助于评估心臟损伤、识别阻塞并确定治疗方案。准确及时的心臟病发作诊断对于降低死亡率、改善患者预后以及预防与心臟事件相关的併发症至关重要。

根据《世界心臟报告》，心血管疾病持续影响全球超过5亿人。

越来越多采用就地检验设备

心臟病诊断市场的成长得益于照护现场(POC) 设备的日益普及，这些设备能够在床边或急诊室快速准确地检测心臟生物标记。此类设备显着缩短了检测时间，确保及时进行临床干预并改善患者预后。对分散式医疗保健和紧急应变效率的日益重视，正在推动全球范围内的普及。此外，可携式诊断平台的技术进步也促进了即时诊断的普及，使其成为心臟病诊断领域的关键驱动力。

农村地区获得诊断的机会有限

阻碍市场成长的一个重要因素是农村和偏远地区难以获得先进的诊断设施。基础设施缺口、训练有素的医务人员缺乏以及高昂的设备成本限制了这些地区采用先进的诊断工具。因此，心臟疾病的延迟诊断会导致治疗效果不佳，并扩大医疗保健差距。虽然都市区受益于科技的快速普及，但农村医疗保健系统仍面临挑战。这种差距减缓了整体市场渗透率，并限制了公平获得诊断服务的机会。

整合人工智慧主导的诊断平台

人工智慧 (AI) 与诊断系统的整合为心臟病诊断市场带来了广阔的机会。 AI 平台能够增强对复杂影像和生物标记数据的解读，从而更快、更准确地检测心肌梗塞。数位健康和​​预测分析领域不断增长的投资，支持 AI 在医院网路中的应用。此外，AI主导的决策支援工具可帮助临床医生进行分诊和製定治疗计划。随着 AI 技术的成熟，它们的整合将增强精准诊断，最终彻底改变全球心臟护理路径。

误诊风险影响临床信心水平

儘管技术不断进步，误诊风险仍然是心臟病诊断市场的一大威胁。生物标记检测和影像检查中的假阳性和假阴性结果会损害医生的信心，并对患者安全产生负面影响。这可能导致不必要的治疗和介入缺失，从而削弱人们对诊断系统的信心。此外，对不同平台之间测试准确性差异的担忧进一步加剧了这一威胁。因此，持续的临床检验和标准化对于降低风险和维持诊断信心至关重要。

COVID-19的影响：

新冠疫情严重扰乱了心臟病诊断市场，医院优先考虑新冠治疗，并推迟了选择性心臟检查。患者不愿前往医疗机构就诊，进一步减少了诊断量。然而，这场危机加速了就地检验和远端医疗主导的心臟监测解决方案的采用。疫情后的復苏再次强调了早期心臟诊断的重要性，医疗系统也在投资建立具有韧性的诊断基础设施。因此，新冠疫情既是短期的挫折，也是心臟诊断领域创新和去中心化的长期催化剂。

预计设备部门将成为预测期内最大的部门

由于设备在医院、诊断实验室和急救医疗中心的广泛应用，预计在预测期内将占据最大的市场份额。分析仪、影像设备和生物标记检测系统等设备构成了心臟诊断的支柱，确保评估的准确性和及时性。对技术先进和自动化诊断设备日益增长的需求进一步巩固了其主导地位。此外，成像模式和生物标记平台的持续技术创新正在增强设备领域作为市场主要贡献者的地位。

预测期内，超音波心动图领域预计将以最高复合年增长率成长

超音波心动图领域预计将在预测期内实现最高成长率，这得益于其非侵入性特性和提供即时心臟成像的能力。心血管疾病的日益普及以及对超音波诊断的偏好正在推动需求成长。 3D超音波心动图和可携式超音波心动图系统的进步正在提高临床诊断的准确性和可及性。此外，超音波心动图在急诊和门诊环境中已成为快速评估心臟功能的必备工具。技术创新与应用的融合使心臟超音波图成为成长最快的诊断领域。

比最大的地区

在预测期内，由于患者人数不断增加、心血管疾病盛行率不断上升以及医疗基础设施不断完善，亚太地区预计将占据最大的市场份额。政府加强早期疾病检测系统的倡议不断增多，将进一步推动其应用。此外，在新兴经济体中，经济高效的诊断解决方案的普及率和可近性也在不断提高。快速的都市化和生活方式的改变加剧了心臟病风险因素，从而推动了对诊断的需求。这些因素共同使亚太地区成为心臟病诊断的领先区域市场。

复合年增长率最高的地区：

由于先进的医疗基础设施、高度的诊断意识以及快速的技术应用，北美预计将在预测期内实现最高的复合年增长率。大型诊断公司的强大影响力和大量的研发投入正在加速心臟检测解决方案的技术创新。优惠的报销框架正在推动先进诊断技术的市场渗透。此外，对精准诊断和数位健康整合的需求不断增长，也加速了相关技术的普及。随着心血管疾病负担的持续增加，北美正成为成长最快的区域市场。

免费客製化服务

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 全面分析其他市场参与者（最多 3 家公司）
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球心臟病诊断市场（按产品）

  • 装置
  • 耗材
  • 软体
  • 服务

6. 全球心臟病诊断市场（依测试类型）

  • 心电图（ECG）
  • 血液检查
  • 心臟超音波图
  • 冠动脉摄影术

7. 全球心臟病诊断市场（依生物标记）

  • 肌钙蛋白
  • 肌酸激酶同功酶（CK-MB）
  • 肌红蛋白
  • C反应蛋白（CRP）
  • 脑钠肽（BNP）

8. 全球心臟病诊断市场（以影像方式）

  • 心臟超音波图
  • 电脑断层扫描（CT）
  • 磁振造影（MRI）
  • 核子造影
  • X射线

9. 全球心臟病诊断市场（依诊断方法）

  • 实验室检查
  • 影像检查
  • 就地检验

第 10 章。按年龄组别分類的全球心臟病诊断市场

  • 40岁以下
  • 60岁或以上

第 11 章。全球心臟病诊断市场（按应用）

  • 紧急诊断
  • 风险评估
  • 治疗监测
  • 调查应用

第 12 章。全球心臟病诊断市场（按最终用户）

  • 医院
  • 诊断中心
  • 门诊手术中心
  • 研究办公室

13. 全球心臟病诊断市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十四章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第 15 章：公司概况

  • Abbott Laboratories
  • Siemens Healthineers
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare
  • Philips Healthcare
  • Bio-Rad Laboratories Inc.
  • Beckman Coulter（Danaher Corporation）
  • Thermo Fisher Scientific Inc.
  • Qiagen NV
  • Randox Laboratories Ltd.
  • Ortho Clinical Diagnostics
  • Becton, Dickinson and Company（BD）
  • CardioDx Inc.
  • Biomerica Inc.
  • Luminex Corporation
  • BioMerieux SA
  • Nova Biomedical
  • Nihon Kohden Corporation
  • Response Biomedical Corporation
  • Critical Diagnostics
Product Code: SMRC30736

According to Stratistics MRC, the Global Heart Attack Diagnostics Market is accounted for $12.5 billion in 2025 and is expected to reach $21.8 billion by 2032 growing at a CAGR of 8.2% during the forecast period. Heart Attack Diagnostics are medical procedures, tests, and devices used to detect and confirm myocardial infarction, a condition caused by restricted blood flow to the heart. These diagnostics include blood tests for cardiac biomarkers, electrocardiograms (ECG), imaging modalities, and stress tests. They help evaluate heart damage, identify blockages, and guide treatment decisions. Accurate and timely heart attack diagnostics are critical for reducing mortality, improving patient outcomes, and preventing complications related to cardiac events.

According to the World Heart Report, cardiovascular diseases continue to affect more than 500 million people across the globe.

Market Dynamics:

Driver:

Increasing adoption of point-of-care testing devices

The market for heart attack diagnostics is spurred by the rising adoption of point-of-care (POC) testing devices, which enable rapid and accurate detection of cardiac biomarkers at bedside or emergency settings. These devices reduce turnaround times significantly, ensuring timely clinical intervention and improved patient outcomes. Growing emphasis on decentralized healthcare and emergency response efficiency strengthens their adoption globally. Furthermore, technological advancements in portable diagnostic platforms support broader accessibility, making POC testing a pivotal driver in the heart attack diagnostics landscape.

Restraint:

Limited access to diagnostics in rural regions

A significant restraint hindering market growth is the limited access to advanced diagnostic facilities in rural and remote regions. Infrastructure gaps, lack of trained healthcare professionals, and high equipment costs restrict adoption of advanced diagnostic tools in these areas. Consequently, delayed detection of cardiac events leads to poor treatment outcomes, widening healthcare disparities. While urban centers benefit from rapid technological adoption, rural healthcare systems continue to face challenges. This disparity slows overall market penetration and limits equitable diagnostic availability.

Opportunity:

Integration of AI-driven diagnostic platforms

The integration of artificial intelligence (AI) into diagnostic systems presents a promising opportunity for the heart attack diagnostics market. AI-enabled platforms enhance interpretation of complex imaging and biomarker data, enabling faster and more accurate detection of myocardial infarction. Growing investments in digital health and predictive analytics support AI adoption across hospital networks. Additionally, AI-driven decision support tools aid clinicians in triage and treatment planning. As AI technologies mature, their integration enhances precision diagnostics, ultimately revolutionizing cardiac care pathways worldwide.

Threat:

Risk of misdiagnosis affecting clinical trust levels

Despite technological advancements, the risk of misdiagnosis remains a critical threat in the heart attack diagnostics market. False positives or negatives in biomarker assays or imaging tests can undermine physician confidence and negatively impact patient safety. Such occurrences may lead to unnecessary treatments or missed interventions, eroding trust in diagnostic systems. Additionally, concerns over variability in test accuracy across different platforms intensify this threat. Sustained clinical validation and standardization are therefore crucial to mitigate risks and preserve diagnostic credibility.

Covid-19 Impact:

The COVID-19 pandemic significantly disrupted the heart attack diagnostics market, with hospitals prioritizing COVID care and delaying elective cardiac testing. Patient reluctance to visit healthcare facilities further reduced diagnostic volumes. However, the crisis accelerated adoption of point-of-care testing and telehealth-driven cardiac monitoring solutions. Post-pandemic recovery has seen renewed emphasis on early cardiac diagnostics, with healthcare systems investing in resilient diagnostic infrastructure. Consequently, COVID-19 served as both a short-term setback and a long-term catalyst for innovation and decentralization in cardiac diagnostics.

The instruments segment is expected to be the largest during the forecast period

The instruments segment is expected to account for the largest market share during the forecast period, owing to their widespread use in hospitals, diagnostic laboratories, and emergency care centers. Instruments such as analyzers, imaging devices, and biomarker detection systems form the backbone of cardiac diagnostics, ensuring accurate and timely assessments. Growing demand for technologically advanced and automated diagnostic instruments further consolidates their dominance. Moreover, continuous innovation in imaging modalities and biomarker platforms reinforces the instruments segment as the market's leading contributor.

The echocardiogram segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the echocardiogram segment is predicted to witness the highest growth rate, impelled by its non-invasive nature and ability to provide real-time cardiac imaging. The increasing prevalence of cardiovascular diseases and preference for ultrasound-based diagnostics fuel demand. Advancements in 3D and portable echocardiography systems enhance clinical accuracy and accessibility. Additionally, echocardiograms are becoming integral in emergency and outpatient settings for rapid heart function assessment. This convergence of innovation and adoption establishes echocardiography as the fastest-growing diagnostic segment.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by its expanding patient pool, rising cardiovascular disease prevalence, and growing healthcare infrastructure. Increasing government initiatives to strengthen early disease detection systems further enhance adoption. Moreover, the presence of cost-effective diagnostic solutions in emerging economies boosts accessibility. Rapid urbanization and lifestyle changes exacerbate cardiac risk factors, fueling diagnostic demand. Collectively, these elements position Asia Pacific as the leading regional market in heart attack diagnostics.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR attributed to advanced healthcare infrastructure, high diagnostic awareness, and rapid technology adoption. Strong presence of leading diagnostic companies and extensive R&D investments accelerate innovation in cardiac testing solutions. Favorable reimbursement frameworks support market penetration of advanced diagnostics. Additionally, growing demand for precision diagnostics and digital health integration amplifies adoption. As cardiovascular burden continues to rise, North America emerges as the fastest-expanding regional market.

Key players in the market

Some of the key players in Heart Attack Diagnostics Market include Abbott Laboratories, Siemens Healthineers, F. Hoffmann-La Roche Ltd., GE Healthcare, Philips Healthcare, Bio-Rad Laboratories, Beckman Coulter (Danaher), Thermo Fisher Scientific Inc., Qiagen N.V., Randox Laboratories, Ortho Clinical Diagnostics, Becton, Dickinson and Company, CardioDx Inc., Biomerica Inc., Luminex Corporation, BioMerieux SA, Nova Biomedical, Nihon Kohden Corporation, Response Biomedical Corporation, and Critical Diagnostics.

Key Developments:

In May 2025, Roche Diagnostics (F. Hoffmann-La Roche Ltd) received FDA 510(k) clearance for an enhanced version of its Elecsys(R) Troponin T high-sensitivity test, aimed at providing even more precise risk stratification for patients presenting with chest pain in the emergency department.

In April 2025, Siemens Healthineers announced the U.S. launch of its Atellica(R) CI1900 Integrated Solution, which combines core laboratory and cardiac testing to deliver a consolidated troponin result from a single platform, improving workflow efficiency for heart attack diagnosis.

In March 2025, Abbott Laboratories initiated a major clinical study across 100 sites in the U.S. and Europe to expand the clinical claims for its Alinity i High-Sensitivity Troponin-I assay, focusing on rapid rule-out protocols to help reduce emergency room overcrowding.

Products Covered:

  • Instruments
  • Consumables
  • Software
  • Services

Test Types Covered:

  • Electrocardiogram (ECG)
  • Blood Tests
  • Echocardiogram
  • Coronary Angiography

Biomarkers Covered:

  • Troponin
  • Creatine Kinase-MB (CK-MB)
  • Myoglobin
  • C-Reactive Protein (CRP)
  • Brain Natriuretic Peptide (BNP)

Imaging Modalities Covered:

  • Echocardiography
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
  • Nuclear Imaging
  • X-ray

Diagnosis Methods Covered:

  • Laboratory Testing
  • Imaging Testing
  • Point-of-Care Testing

Age Groups Covered:

  • Below 40 Years
  • Above 60 Years

Applications Covered:

  • Emergency Diagnosis
  • Risk Assessment
  • Therapy Monitoring
  • Research Applications

End Users Covered:

  • Hospitals
  • Diagnostic Centers
  • Ambulatory Surgical Centers
  • Research Laboratories

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Heart Attack Diagnostics Market, By Product

  • 5.1 Introduction
  • 5.2 Instruments
  • 5.3 Consumables
  • 5.4 Software
  • 5.5 Services

6 Global Heart Attack Diagnostics Market, By Test Type

  • 6.1 Introduction
  • 6.2 Electrocardiogram (ECG)
  • 6.3 Blood Tests
  • 6.4 Echocardiogram
  • 6.5 Coronary Angiography

7 Global Heart Attack Diagnostics Market, By Biomarker

  • 7.1 Introduction
  • 7.2 Troponin
  • 7.3 Creatine Kinase-MB (CK-MB)
  • 7.4 Myoglobin
  • 7.5 C-Reactive Protein (CRP)
  • 7.6 Brain Natriuretic Peptide (BNP)

8 Global Heart Attack Diagnostics Market, By Imaging Modality

  • 8.1 Introduction
  • 8.2 Echocardiography
  • 8.3 Computed Tomography (CT)
  • 8.4 Magnetic Resonance Imaging (MRI)
  • 8.5 Nuclear Imaging
  • 8.6 X-ray

9 Global Heart Attack Diagnostics Market, By Diagnosis Method

  • 9.1 Introduction
  • 9.2 Laboratory Testing
  • 9.3 Imaging Testing
  • 9.4 Point-of-Care Testing

10 Global Heart Attack Diagnostics Market, By Age Group

  • 10.1 Introduction
  • 10.2 Below 40 Years
  • 10.3 Above 60 Years

11 Global Heart Attack Diagnostics Market, By Application

  • 11.1 Introduction
  • 11.2 Emergency Diagnosis
  • 11.3 Risk Assessment
  • 11.4 Therapy Monitoring
  • 11.5 Research Applications

12 Global Heart Attack Diagnostics Market, By End User

  • 12.1 Introduction
  • 12.2 Hospitals
  • 12.3 Diagnostic Centers
  • 12.4 Ambulatory Surgical Centers
  • 12.5 Research Laboratories

13 Global Heart Attack Diagnostics Market, By Geography

  • 13.1 Introduction
  • 13.2 North America
    • 13.2.1 US
    • 13.2.2 Canada
    • 13.2.3 Mexico
  • 13.3 Europe
    • 13.3.1 Germany
    • 13.3.2 UK
    • 13.3.3 Italy
    • 13.3.4 France
    • 13.3.5 Spain
    • 13.3.6 Rest of Europe
  • 13.4 Asia Pacific
    • 13.4.1 Japan
    • 13.4.2 China
    • 13.4.3 India
    • 13.4.4 Australia
    • 13.4.5 New Zealand
    • 13.4.6 South Korea
    • 13.4.7 Rest of Asia Pacific
  • 13.5 South America
    • 13.5.1 Argentina
    • 13.5.2 Brazil
    • 13.5.3 Chile
    • 13.5.4 Rest of South America
  • 13.6 Middle East & Africa
    • 13.6.1 Saudi Arabia
    • 13.6.2 UAE
    • 13.6.3 Qatar
    • 13.6.4 South Africa
    • 13.6.5 Rest of Middle East & Africa

14 Key Developments

  • 14.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 14.2 Acquisitions & Mergers
  • 14.3 New Product Launch
  • 14.4 Expansions
  • 14.5 Other Key Strategies

15 Company Profiling

  • 15.1 Abbott Laboratories
  • 15.2 Siemens Healthineers
  • 15.3 F. Hoffmann-La Roche Ltd.
  • 15.4 GE Healthcare
  • 15.5 Philips Healthcare
  • 15.6 Bio-Rad Laboratories Inc.
  • 15.7 Beckman Coulter (Danaher Corporation)
  • 15.8 Thermo Fisher Scientific Inc.
  • 15.9 Qiagen N.V.
  • 15.10 Randox Laboratories Ltd.
  • 15.11 Ortho Clinical Diagnostics
  • 15.12 Becton, Dickinson and Company (BD)
  • 15.13 CardioDx Inc.
  • 15.14 Biomerica Inc.
  • 15.15 Luminex Corporation
  • 15.16 BioMerieux SA
  • 15.17 Nova Biomedical
  • 15.18 Nihon Kohden Corporation
  • 15.19 Response Biomedical Corporation
  • 15.20 Critical Diagnostics

List of Tables

  • Table 1 Global Heart Attack Diagnostics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Heart Attack Diagnostics Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Heart Attack Diagnostics Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 4 Global Heart Attack Diagnostics Market Outlook, By Consumables (2024-2032) ($MN)
  • Table 5 Global Heart Attack Diagnostics Market Outlook, By Software (2024-2032) ($MN)
  • Table 6 Global Heart Attack Diagnostics Market Outlook, By Services (2024-2032) ($MN)
  • Table 7 Global Heart Attack Diagnostics Market Outlook, By Test Type (2024-2032) ($MN)
  • Table 8 Global Heart Attack Diagnostics Market Outlook, By Electrocardiogram (ECG) (2024-2032) ($MN)
  • Table 9 Global Heart Attack Diagnostics Market Outlook, By Blood Tests (2024-2032) ($MN)
  • Table 10 Global Heart Attack Diagnostics Market Outlook, By Echocardiogram (2024-2032) ($MN)
  • Table 11 Global Heart Attack Diagnostics Market Outlook, By Coronary Angiography (2024-2032) ($MN)
  • Table 12 Global Heart Attack Diagnostics Market Outlook, By Biomarker (2024-2032) ($MN)
  • Table 13 Global Heart Attack Diagnostics Market Outlook, By Troponin (2024-2032) ($MN)
  • Table 14 Global Heart Attack Diagnostics Market Outlook, By Creatine Kinase-MB (CK-MB) (2024-2032) ($MN)
  • Table 15 Global Heart Attack Diagnostics Market Outlook, By Myoglobin (2024-2032) ($MN)
  • Table 16 Global Heart Attack Diagnostics Market Outlook, By C-Reactive Protein (CRP) (2024-2032) ($MN)
  • Table 17 Global Heart Attack Diagnostics Market Outlook, By Brain Natriuretic Peptide (BNP) (2024-2032) ($MN)
  • Table 18 Global Heart Attack Diagnostics Market Outlook, By Imaging Modality (2024-2032) ($MN)
  • Table 19 Global Heart Attack Diagnostics Market Outlook, By Echocardiography (2024-2032) ($MN)
  • Table 20 Global Heart Attack Diagnostics Market Outlook, By Computed Tomography (CT) (2024-2032) ($MN)
  • Table 21 Global Heart Attack Diagnostics Market Outlook, By Magnetic Resonance Imaging (MRI) (2024-2032) ($MN)
  • Table 22 Global Heart Attack Diagnostics Market Outlook, By Nuclear Imaging (2024-2032) ($MN)
  • Table 23 Global Heart Attack Diagnostics Market Outlook, By X-ray (2024-2032) ($MN)
  • Table 24 Global Heart Attack Diagnostics Market Outlook, By Diagnosis Method (2024-2032) ($MN)
  • Table 25 Global Heart Attack Diagnostics Market Outlook, By Laboratory Testing (2024-2032) ($MN)
  • Table 26 Global Heart Attack Diagnostics Market Outlook, By Imaging Testing (2024-2032) ($MN)
  • Table 27 Global Heart Attack Diagnostics Market Outlook, By Point-of-Care Testing (2024-2032) ($MN)
  • Table 28 Global Heart Attack Diagnostics Market Outlook, By Age Group (2024-2032) ($MN)
  • Table 29 Global Heart Attack Diagnostics Market Outlook, By Below 40 Years (2024-2032) ($MN)
  • Table 30 Global Heart Attack Diagnostics Market Outlook, By Above 60 Years (2024-2032) ($MN)
  • Table 31 Global Heart Attack Diagnostics Market Outlook, By Application (2024-2032) ($MN)
  • Table 32 Global Heart Attack Diagnostics Market Outlook, By Emergency Diagnosis (2024-2032) ($MN)
  • Table 33 Global Heart Attack Diagnostics Market Outlook, By Risk Assessment (2024-2032) ($MN)
  • Table 34 Global Heart Attack Diagnostics Market Outlook, By Therapy Monitoring (2024-2032) ($MN)
  • Table 35 Global Heart Attack Diagnostics Market Outlook, By Research Applications (2024-2032) ($MN)
  • Table 36 Global Heart Attack Diagnostics Market Outlook, By End User (2024-2032) ($MN)
  • Table 37 Global Heart Attack Diagnostics Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 38 Global Heart Attack Diagnostics Market Outlook, By Diagnostic Centers (2024-2032) ($MN)
  • Table 39 Global Heart Attack Diagnostics Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 40 Global Heart Attack Diagnostics Market Outlook, By Research Laboratories (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.